Novartis started 2021 on a cautious note, mainly due to sustained pandemic impediments and tough comps, i.e. panic-buying-driven Q1 20. While the group is expected to benefit from favourable comps in Q2, further performance recovery – backed by the slew of innovations across therapeutic areas – remains on track. Although the near term could continue being impacted by pandemic-related adversities, the sturdy ex. oncology portfolio performance and various cost containment measures should provide v ....
28 Apr 2021
Decently poised, after an acceptable Q1
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Decently poised, after an acceptable Q1
Novartis started 2021 on a cautious note, mainly due to sustained pandemic impediments and tough comps, i.e. panic-buying-driven Q1 20. While the group is expected to benefit from favourable comps in Q2, further performance recovery – backed by the slew of innovations across therapeutic areas – remains on track. Although the near term could continue being impacted by pandemic-related adversities, the sturdy ex. oncology portfolio performance and various cost containment measures should provide v ....